Pfizer Partners with Mylan for Enhanced Distribution of Key Brands

Pfizer Ltd's board has greenlit a marketing and supply agreement with Mylan Pharmaceuticals Pvt Ltd to enhance distribution and presence of Ativan and Pacitane in India. The five-year deal aims to leverage Mylan's strong central nervous system therapy presence with specialists like neurologists and psychiatrists.

Pfizer Ltd announced that its board has approved a strategic marketing and supply agreement with Mylan Pharmaceuticals Pvt Ltd, aiming to expand the reach of two significant brands, Ativan and Pacitane.

Ativan is primarily used for treating anxiety disorders, while Pacitane is prescribed as an adjunct therapy for various forms of Parkinsonism. The agreement is slated to last five years and is limited to the Indian market.

According to Pfizer, leveraging Mylan's robust presence in the central nervous system therapy domain—especially among neurologists and psychiatrists—will substantially enhance product distribution and clinical presence.